Presentation is loading. Please wait.

Presentation is loading. Please wait.

Buprenorphine Daryl Shorter, MD Michael E. DeBakey VA Medical Center Menninger Department of Psychiatry and Behavioral Science Baylor College of Medicine.

Similar presentations


Presentation on theme: "Buprenorphine Daryl Shorter, MD Michael E. DeBakey VA Medical Center Menninger Department of Psychiatry and Behavioral Science Baylor College of Medicine."— Presentation transcript:

1 Buprenorphine Daryl Shorter, MD Michael E. DeBakey VA Medical Center Menninger Department of Psychiatry and Behavioral Science Baylor College of Medicine 1

2 Alcohol Medical Scholars Program2 22.5 million Americans (8.7%) current users of illicit substances 2.33 million persons with Opioid Use Disorder 426,000 persons with heroin abuse or dependence 1.8 million persons with pain reliever abuse or dependence

3 This Lecture Reviews 1.Definitions 2.Course of Opioid Use Disorder (OUD) 3.Treatment of OUD 4.Role of buprenorphine in long-term Rx 3Alcohol Medical Scholars Program

4 Opioid Brain Effects Decrease pain (via μ-opioid receptor) Suppress cough Increase constipation Cause euphoria (μ-opioid receptor) 4Alcohol Medical Scholars Program

5 Opioids Heroin – no medical use Morphine – Rx for pain All prescription pain meds (unless anti- inflammatory) – Oxycodone (Oxycontin) – Hydrocodone (Vicodin, Lorcet, Lortab) – Methadone (Dolophine) – Buprenorphine (Subutex) – Tramadol (Ultram) 5Alcohol Medical Scholars Program

6 DSM-5 Opioid Use Disorder Tolerance Withdrawal Attempts to cut down Much time spent using Use larger amounts Neglecting roles Hazardous use Physical/psychological problems from use Social/interpersonal problems from use Activities given up Craving 6Alcohol Medical Scholars Program

7 Opioid Withdrawal Dysphoric (sad) mood Muscle aches Lacrimation (tearing) or rhinorrhea (runny nose) Pupillary dilation, piloerection (goose flesh), or sweating Nausea/vomiting Diarrhea Yawning Fever Insomnia 7Alcohol Medical Scholars Program

8 Opioid Overdose 2 nd highest cause of accidental death 17,000 opioid overdose deaths (2010) Cause of death = respiratory depression ~7 non-fatal OD for every fatal OD 8Alcohol Medical Scholars Program

9 Opioid Overdose ↓ consciousness ↓ respirations (< 12/min) Miotic (pinpoint) pupils Evidence of opioid use (needle track marks) Management: Opioid antagonist, naloxone 9Alcohol Medical Scholars Program

10 This Lecture Reviews 1.Definitions 2.Course of Opioid Use Disorder (OUD) 3.Treatment of OUD 4.Role of buprenorphine in long-term Rx 10Alcohol Medical Scholars Program

11 Course of OUD OUD Nonmedical Use Prescription Rx or street drugs Exposure to Pain Relievers or seek opioid high 11Alcohol Medical Scholars Program

12 Health Risks OUD Accidental injury – 2-5x ↑ risk of falls & fractures – ~3x ↑ risk of mortality from vehicular accidents 4x ↑ risk of overall mortality ↑ risk of HIV & Hepatitis C 12Alcohol Medical Scholars Program

13 Social Consequences ↑ Criminal behavior & crime-related costs Education –  GPA; ↑ truancy Violence Loss job and family 13Alcohol Medical Scholars Program

14 Relapse 6 months after treatment ~50% abstinent 10 years after treatment ~25% abstinent There is a need for effective treatment. 14Alcohol Medical Scholars Program

15 This Lecture Reviews 1.Definitions 2.Course of Opioid Use Disorder (OUD) 3.Treatment of OUD 4.Role of buprenorphine in long-term Rx 15Alcohol Medical Scholars Program

16 Goals of OUD Treatment 1. ↓ withdrawal symptoms 2. ↓ craving 3. Prevent relapse 4. ↑ physiologic state/ improve functioning 16Alcohol Medical Scholars Program

17 Case - Jimmy 32y male, presents to ER Reports 12+ year hx of opioid misuse Last use of heroin ~12 hours ago Anxious, sweating, nauseous, pupils dilated 17Alcohol Medical Scholars Program

18 Clinical Opioid Withdrawal Scale 11-item COWS assessment: pulse, sweating, pupil size, yawning, anxiety Scores characterize withdrawal: – 5-12 = mild – 13-24 = moderate – 25-36 = moderately severe – ≥36 = severe 18Alcohol Medical Scholars Program

19 Withdrawal Management Use clonidine (Catapres) to  withdrawal – α2-adrenergic agonist to  adrenalin – Treats hypertension Rx other symptom as needed – Loperamide (Imodium) for diarrhea – Ibuprofen (Advil) for bone/muscle pain – Medications for insomnia 19Alcohol Medical Scholars Program

20 Withdrawal Management (2) Symptom-triggered clonidine Rx – For COWS > 8, give 0.1-0.2mg clonidine – On day 1, target dose of 0.3-0.6mg – May  to 0.6-1.2mg/day, as necessary – Once stabilized, reduce daily dose by 50% per day 20Alcohol Medical Scholars Program

21 Clonidine Agonist Opioid Withdrawal Antagonist Agonist Long term Rx of OUD 21Alcohol Medical Scholars Program

22 Withdrawal Management (3) Use opioid agonist to  symptoms Methadone – Up to 30mg/day –  10-20% every 1-2 days over 2-3 weeks – Better than α2-adrenergic agonist based Rx Buprenorphine – Up to 8mg/day – ↓ by 2mg every 1-2 days over 7-10 days 22Alcohol Medical Scholars Program

23 Clonidine Agonist Opioid Withdrawal Antagonist Agonist Long term Rx of OUD 23Alcohol Medical Scholars Program

24 Long-term Rx of OUD Opioid Antagonist Therapy – Intramuscular naltrexone (Trexan) Administer every 30 days Prevents opioid high Low compliance – No other FDA-approved medications 24Alcohol Medical Scholars Program

25 Long-term Rx of OUD (2) Methadone maintenance treatment (MMT) – Taken daily by mouth – Obtained through federally-regulated program – Optimal dose varies (target = 80mg/day) -- Must ↑ dose slowly to avoid OD 25Alcohol Medical Scholars Program

26 MMT Drawbacks Overdose common in early treatment Cannot be prescribed from general practice Strict government control and paperwork Stigma of daily clinic attendance 26Alcohol Medical Scholars Program

27 This Lecture Reviews 1.Definitions 2.Course of Opioid Use Disorder (OUD) 3.Treatment of OUD 4.Role of buprenorphine in long-term Rx 27Alcohol Medical Scholars Program

28 Office-Based Buprenorphine Taken daily, sublingually Rx in offices of physicians with special training Individual dose varies (target = 16-24mg/day) Daily visits not necessary 28Alcohol Medical Scholars Program

29 Buprenorphine Pharmacology Partial agonist at μ -opioid receptor Slow dissociation from receptor Half-life = 24-36 hrs Metabolizes quickly, if give orally So Rx is sublingual or buccal 29Alcohol Medical Scholars Program

30 Buprenorphine Pharmacology (2) Clinical impact – Less subjective euphoria than methadone – Long-lasting clinical action – Partially blocks intoxication – Reduced overdose risk 30Alcohol Medical Scholars Program

31 Formulations Buprenorphine alone (Subutex) Buprenorphine + naloxone (Suboxone) – Naloxone = antagonist –  risk of diversion and IV misuse – Combined in 4 mg bup:1 mg naloxone Combo in sublingual or buccal film 31Alcohol Medical Scholars Program

32 More Buprenorphine Info Side effects – Neuro: Sedation, dizziness, headache – GI: Constipation, nausea/vomiting – Respiratory depression Availability and cost – Prescribed by MDs with special training – Reimbursed by Medicaid, health insurances --But costs more than methadone 32Alcohol Medical Scholars Program

33 Buprenorphine Treatment Initiation – Goal: avoid precipitated withdrawal & OD – Patient stops opioid misuse 12-36 hrs prior – Patient demonstrates early withdrawal COWS rating > 8 33Alcohol Medical Scholars Program

34 Buprenorphine Induction Induction phase (days 1-7) – Day 1 First dose = 4mg Assess for adverse effects Repeat 4mg dose if withdrawal symptoms persist Maximum dose day 1 = 8 mg 34Alcohol Medical Scholars Program

35 Buprenorphine Induction (2) Days 2-7 –  dose until withdrawal symptoms  (w/in 2 hrs) – Day 2 dose: often  to 16mg –  dose by Day 7 (usual to 8 – 24mg/day) 35Alcohol Medical Scholars Program

36 Buprenorphine Stabilization Weeks 2-8 – Dose adjustment continues (up to 32mg/day) – Characterized by   opioid craving No withdrawal symptoms  or absent opioid misuse 36Alcohol Medical Scholars Program

37 Buprenorphine Maintenance Months 3-12 – Optimal dose reached – Relapse prevention 37Alcohol Medical Scholars Program

38 Buprenorphine Effectiveness Buprenorphine (16mg/day) Better than placebo and naltrexone ↑Treatment retention  Opioid positive urines 38Alcohol Medical Scholars Program

39 Buprenorphine v. Methadone Both improve outcomes Methadone → greater patient retention Buprenorphine benefits Office-based Rx Safer during induction 39Alcohol Medical Scholars Program

40 Conclusions OUD is common and dangerous Buprenorphine is A partial μ -opioid receptor agonist Is safer Is effective for office-based Rx Combined with naloxone → ↓ misuse 40Alcohol Medical Scholars Program


Download ppt "Buprenorphine Daryl Shorter, MD Michael E. DeBakey VA Medical Center Menninger Department of Psychiatry and Behavioral Science Baylor College of Medicine."

Similar presentations


Ads by Google